title: Analysis of phenotypic and functional changes during ganglioside-induced inhibition of human T cell proliferation.
abstract: Glycosphingolipids added to the cell culture medium can be incorporated into the plasma membrane and interfere with the growth of certain cell types. In the past years, previous reports have shown that gangliosides, a class of glycosphingolipids bearing sialic acid can inhibit antigen or mitogen induced T cell proliferative responses in vitro. We report here that the inhibition of PHA induced proliferation by the trisialoganglioside GT1b was not reversed by addition of exogenous IL-1, IL-2, TPA and calcium ionophore. Furthermore, GT1b did not affect IL-2 production by activated T cells. In addition, GT1b ganglioside could also decrease strongly the expression of the T cell antigens CD3, CD2, CD4, CD8 and the alpha/beta T cell receptor antigenic complex whereas it did not affect HLA-class I antigens. By contrast, GT1b modulated only partially membrane expression of activation antigens such as CD25 (Tac) and transferrin receptor and increased the expression of HLA-class II antigens. Moreover CD25 messenger RNA induction was not affected by GT1b treatment of PHA-stimulated T cells. Our results demonstrate that gangliosides, in spite of their anti-proliferative capacity and their modulation effect on T cell antigen membrane expression, do not prevent the progression of T cells into early stages of the activation process.
authors.affiliation: Laboratorie d'Immuno-biologie des Tumeurs, Institut Gustave Roussy, Villejuif, France.
authors.forename: C
authors.initials: C
authors.lastname: Pique
authors.forename: Y
authors.initials: Y
authors.lastname: Mahé
authors.forename: C
authors.initials: C
authors.lastname: Scamps
authors.forename: C
authors.initials: C
authors.lastname: Tétaud
authors.forename: T
authors.initials: T
authors.lastname: Tursz
authors.forename: J
authors.initials: J
authors.lastname: Wiels
mesh_terms: D015703:Antigens, CD / Q000096:biosynthesis; D001402:B-Lymphocytes / Q000187:drug effects; D015152:Blotting, Northern; D000001:Calcimycin / Q000494:pharmacology; D002478:Cells, Cultured; D005732:Gangliosides / Q000494:pharmacology*; D015395:Histocompatibility Antigens Class I / Q000096:biosynthesis; D006801:Humans; D016130:Immunophenotyping; D066298:In Vitro Techniques; D007375:Interleukin-1 / Q000494:pharmacology; D007376:Interleukin-2 / Q000096:biosynthesis / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects*; D010835:Phytohemagglutinins; D012333:RNA, Messenger / Q000096:biosynthesis; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000096:biosynthesis; D011990:Receptors, Transferrin / Q000096:biosynthesis; D013601:T-Lymphocytes / Q000502:physiology*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
chemical_list: D015703:Antigens, CD; D005732:Gangliosides; D015395:Histocompatibility Antigens Class I; D007375:Interleukin-1; D007376:Interleukin-2; D010835:Phytohemagglutinins; D012333:RNA, Messenger; D016693:Receptors, Antigen, T-Cell, alpha-beta; D011990:Receptors, Transferrin; D000001:Calcimycin; C016481:trisialoganglioside GT1; D013755:Tetradecanoylphorbol Acetate